Backgrounds/Aims. Watson for Oncology (WFO) is a cognitive technology that processes medical information by analyzing the\nlatest evidence and guidelines. However, studies of the concordance rate betweenWFO and clinicians for advanced gastric cancer\n(AGC) are lacking. Methods.We retrospectively reviewed 65 patients with AGC who consultedWFO and the Gachon Gil Medical\nCenter multidisciplinary team (GMDT) in 2016 and 2017. The recommendations of WFO were compared with the opinions of\nthe GMDT. WFO provided three treatment options: recommended (first treatment option), for consideration (second treatment\noption), and not recommended. Results. In total, 65 patients (mean age 61.0 years; 44 males and 21 females) were included in the\nstudy. Theconcordance rate betweenWFO and theGMDTwas 41.5% (27/65) at the recommended level and 87.7% (57/65) at the for\nconsideration level.Themain causes of discordance betweenWFO and theGMDTwere as follows. First,WFO did not consider the\nmedical history. Second,WFO recommended the use of agents that are considered outdated in Korea. Third, some patients wanted\nto be involved in a clinical trial. Fourth, some patients refused to use the biologic agents recommended byWFO for financial reasons\nas they were not covered by medical insurance. Conclusions.The concordance rate at the recommended level was relatively low but\nwas higher at the for consideration level. Discordances arose mainly from the different medical circumstances at the Gachon Gil\nMedical Center (GMC) and theMemorial Sloan Kettering Cancer Center (MSKCC), the mainWFO consulting center.The utility\nof WFO as a tool for supporting clinical decision making could be further improved by incorporating regional guidelines.
Loading....